INVION LIMITED — Board/Management Information 2018

Mar 21, 2018

ASX / MEDIA ANNOUNCEMENT

==> picture [160 x 53] intentionally omitted <==

CHANGE TO INVION BOARD OF DIRECTORS

Brisbane, Australia and Delaware, United States, 22 March 2018 : Invion Limited (ASX: IVX, “Invion” or “Company”) announces the retirement from the Board, for personal reasons, of Non-executive Director, Mr Warren Brown, effective 22 March 2018.

Mr Brown was appointed Non-executive Director on 4 November 2011, and served during the Company’s 2012 acquisition of Inverseon, Inc. and the recent development and commercialisation transaction for the Photosoft™ asset.

Mr Brown’s retirement from the Board also sees the cessation of appointment of Mr Gregory Brown who had been appointed to act for Mr Warren Brown at any meetings that Mr Warren Brown could not attend.

Dr Greg Collier, Managing Director and Chief Executive Officer of Invion, said: “On behalf of the Board, I thank Warren for his years of commitment to the goals and growth of Invion.”

At the Company’s AGM held 30 November 2017, Invion shareholders approved a commercial transaction with The Cho Group for the global development and Australia/ New Zealand commercialisation rights to the Photosoft[TM] technology, a next-generation Photo Dynamic Therapy (PDT), for the treatment of solid cancers.

Earlier this week, Invion announced that it has signed a Research & Development Alliance Agreement with Hudson Institute, for collaboration on a range of projects on the Photosoft[TM] technology.

Invion also announced the appointment of Dr Andrew Stephens to the scientific and medical advisory board of the Company.

---

Investor enquiries

Managing Director & CEO, Dr Greg Collier T: +61 3 9081 6005 E: investor@inviongroup.com

About Invion

Invion is a clinical-stage life-sciences company that holds the license to the next-generation Photo Dynamic Therapy (PDT), Photosoft[TM] . Photosoft™ is a new generation photosensitiser derived from chlorophyll which is hypothesised to identify and selectively accumulate within solid cancerous tumour tissues. Photosoft™ is activated at multiple light sensitivity ranges across a broad spectrum, and therefore has potential to be targeted to both surface and deep seated tumours. Invion has an agreement with The Cho Group to conduct clinical development of Photosoft™ globally, leveraging the Company’s expertise. The Cho Group will provide non-dilutive funding to Invion for R&D and clinical trials as part of a global development strategy for the asset. Invion has also been granted exclusivity in Australia and New Zealand to commercialise and distribute Photosoft™ for the treatment of cancers. Invion is listed on ASX (ASX:IVX).

Invion Limited ABN 76 094 730 417

722 High Street, East Kew, VIC 3102 Australia P: +61 3 9081 6005 W: www.inviongroup.com